NCT01945606View on ClinicalTrials.gov

Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 29, 2013

Primary Completion Date

September 9, 2014

Study Completion Date

March 17, 2015

Conditions
Heart Failure
Interventions
DRUG

Placebo (treatment 1)

Oral administration of placebo tablets

DRUG

BAY1067197 (treatment 2)

Oral administration of a single dose of 30 mg (3×10 mg Tablet) BAY1067197

Trial Locations (1)

9700 RB

Groningen

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01945606 - Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker | Biotech Hunter | Biotech Hunter